NeuroSense Therapeutics Completes Pre-NDA Process for PrimeC in Canada
NeuroSense Therapeutics has completed a key preparatory step for its PrimeC drug submission to Canadian health authorities. The company aims to file the application in December 2026.
NeuroSense Therapeutics Ltd. has finalized the pre-New Drug Submission (NDS) process for its PrimeC drug candidate with Health Canada. Meeting minutes confirm alignment between the company and the regulatory body regarding the planned content and structure of the submission for amyotrophic lateral sclerosis (ALS).
The company intends to submit the application in December 2026. This milestone signifies progress toward making PrimeC available in the Canadian market. ALS is a progressive neurodegenerative disease with no cure, underscoring the need for new therapeutic options.
NeuroSense Therapeutics is a late-stage clinical biotechnology company focused on developing treatments for neurological disorders. PrimeC is being investigated as a combination therapy designed to slow the progression of ALS and improve patient outcomes.
The biotechnology firm aims to address a significant unmet medical need for ALS patients. The agreement with Health Canada paves the way for NeuroSense to present its clinical trial data and potentially seek market authorization in Canada.